If DPCA buy out PSA research center in China goes well, Dongfeng investing into PSA shall speeds up.
Recently, as reporter known form well-informed source that DPCA buying out PSA research center in China is a selective choice for Dongfeng invests into PSA. If success, it will benefit DPCA.
Significant loss PSA is looking for hemostasis ASAP, which prepares to sell its share. Its most important cooperation partner, Dongfeng Auto, becomes its first choice. But for Dongfeng capital exchange condition, Dongfeng wants PSA core technology. Research center may be the breakthrough for the deal.
However, buying out faces a problem that the research center provides support for Changan PSA. It is important for Dongfeng to organize relationship between research center and Changan PSA.
From Jan 1 2014, Gabin becomes an employee of PSA Asian Research Center instead of PSA Finance Research Center. Company will not renew their contact after expired at the end of 2013.
“We have couple employees like this, but some Finance part employees choose back to home country and find another job.”Aninformed source of PSA research center told reporter of .
PSA announces on Dec 12 2013 that its automobile business asset shrinks 1.1 billion Euros. Up to the end of 2012, PSA runs out of cash reserve. Its net debt is around 3 billion Euros. It is expected another 1.5 billion Euro cost in 2014.
Under the background, PSA has sold its branches and part property of parent company. It cuts cost from many aspect, and suspends its investment in China next phrase.
As for research center in Shanghai, PSA planned to invest 1 billion Yuan from 2008 to 2010. It would invest more capital from 2011.
However, after the second phrase investment cut off, the research center does not flourishing as it thought. The informed source told media that at present, chemical work is done by joint venture. And test work is shared with universities like TJU.
